Engineered immune cells offer new hope for Hard-to-Treat blood cancers
Disease control
Recruiting now
This study tests a new treatment called Talikabtagene autoleucel (NexCAR19) for adults with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated May 17, 2026 11:39 UTC